GSK gets EU nod for diabetes drug Eperzan; Shire gets needed shares for $4.2B buyout of ViroPharma;

@FiercePharma: New York plant that makes Diovan is next on Novartis' shutdown list. Story | Follow @FiercePharma

@TracyStaton: Q4 sales up, 2013 down, esp in US: Bristol-Myers Squibb Reports 4th Quarter and Full Year 2013 Results. Release  | Follow @TracyStaton

@EricPFierce: Par's decision to buy JHP for $490M will inject new competition into sterile drug manufacturing. Story | Follow @EricPFierce

@CarlyHFierce: Under investor pressure, Teva chairman pledges smaller, more experienced board. Story | Follow @CarlyHFierce

> EU regulators today recommended approval of GlaxoSmithKline's ($GSK) new Type 2 diabetes drug Eperzan. Story

> Sanofi ($SNY) CEO Chris Viehbacher said buying back the 9% stake that L'Oreal owns in Sanofi would be positive financially, but the idea remains speculative because the shares are not for sale. Story

> The U.K. is considering an early access drug program similar to the FDA's breakthrough designation that gets some drugs to the market more quickly. Story

> Shire ($SHPG) says it has successfully completed its tender offer for all of the outstanding shares of ViroPharma ($VPHM). Release

> A new study says that use of aspirin may help fight a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus. Blog report

Medical Device News

@FierceMedDev: Revenue ticks up as Covidien braces for transition. Story | Follow @FierceMedDev

@MichaelGFierce: Intuitive Surgical released 4th quarter earnings. Report (PDF) | Follow @MichaelGFierce

@EmilyWFierce: Neurons "talk to each other," spread epileptic activity in the brain according to researchers. Release | Follow @EmilyWFierce

@GalenMoore: Grim: FDA warned the VA about these human tissue suppliers. VA kept using them anyway. Story via Bloomberg | Follow @GalenMoore

> FDA grants humanitarian use for Miltenyi's stem cell transplant device. News

> Itamar connects with a U.S. nutrition firm to market its home sleep apnea Dx. More

Biotech News

@FierceBiotech: European regulators hand Novartis a big setback on a top blockbuster prospect. Coverage | Follow @FierceBiotech

@JohnCFierce: All PTC Therapeutics has ever done with ataluren is fail and fail again. Now its stock is down 20% on a completely predictable action by the EMA. More | Follow @JohnCFierce

@DamianFierce: GlaxoSmithKline clears an EU hurdle with its once-delayed GLP-1 diabetes drug. More | Follow @DamianFierce

@EmilyMFierce: Genetic platform developed by University of California, San Diego researchers screens marine microbiota for new compounds. Story from FierceBiotech Research | Follow @EmilyMFierce

> Biopharma's middle class spent big in 2013, but price tags are on the rise. Story

And Finally... Bayer CEO Marijn Dekkers has come under fire for reportedly saying "We did not develop this medicine (Nexavar) for Indians" but for patients who could pay for it in response to Indian regulators approving a generic of the drug in that country in 2012. Story

Suggested Articles

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.